HOME > TOP STORIES

TOP STORIES

BUSINESS GSK Exec Tapped as Takeda’s Next President, 1st Non-Japanese to Lead Japan Juggernaut

December 2, 2013
BUSINESS AnGes MG to Resume Collategene Development for Critical Limb Ischemia Treatment: President Yamada

November 29, 2013
REGULATORY MHLW Proposes to “Institutionalize” New Drug Premium; Equivocal Wording Draws Fire at CSIMC

November 28, 2013
BUSINESS President Hasegawa of Takeda Confident About Achieving Targets in Midterm Growth Strategy; Company to Appoint CIO

November 28, 2013
BUSINESS Azilva Tops Physician “Mind Share” Ranking in GP, HP Markets in October: New Survey

November 27, 2013
BUSINESS Eisai to Take Over Marketing Rights for Gliadel from Nobelpharma

November 27, 2013
ACADEMIA All Clinical Studies Should Follow GCP Requirements: Ex-AZ Chairman Kato

November 26, 2013
BUSINESS Farmorubicin Approved for Additional Dosage and Administration for Hepatic Cancer: Pfizer Japan

November 26, 2013
BUSINESS AZ Aims to Maintain Presence in Oncology Field Via Partnerships until Launch of New Drugs

November 25, 2013
BUSINESS Takeda Deploys Cardiovascular, Diabetes Sales Reps for Comprehensive Detailing Activities for Lifestyle Diseases

November 22, 2013
BUSINESS Japan Diovan Sales Down 15.7% in July-September: IMS

November 22, 2013
REGULATORY JGA President Opposes 50% Rule for Generics, CSIMC Subcommittee Members Disagree

November 21, 2013
BUSINESS Japan Now Part of Global PIII Clinical Study for MLN9708: Takeda

November 21, 2013
BUSINESS US Pfizer Plans Simultaneous, Global Filing of Five Biosimilars, Eyes Japan Biosimilar Market Entry

November 20, 2013
ACADEMIA JAMS’ Draft of Revised Guidelines Ups Ante for COI Disclosures in Clinical Trials

November 19, 2013
REGULATORY PAFSC’s 1st Committee on Drugs to Review Astellas’s SGLT-2 Inhibitor Ipragliflozin on Nov. 29

November 19, 2013
BUSINESS Takeda, Eisai Earnings Show Signs of Bottoming Out, on Path to Recovery

November 18, 2013
BUSINESS Sales of Major Japanese Drug Makers Soar 8.1% on Weak Yen, Steady Japan Business

November 15, 2013
REGULATORY Health Ministry Proposes to Set First Generic Prices at Half of Brand Name Drug Prices

November 14, 2013
BUSINESS Otsuka Holdings Notches Double-Digit Sales Growth in April-September, Weaker Yen Comes as Boon

November 14, 2013

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…